» Articles » PMID: 36401107

Envisioning Minimally Disruptive Opioid Use Disorder Care

Overview
Publisher Springer
Specialty General Medicine
Date 2022 Nov 18
PMID 36401107
Authors
Affiliations
Soon will be listed here.
Abstract

Most people who need and want treatment for opioid addiction cannot access it. Among those who do get treatment, only a fraction receive evidence-based, life-saving medications for opioid use disorder (MOUD). MOUD access is not simply a matter of needing more clinicians or expanding existing treatment capacity. Instead, many facets of our health systems and policies create unwarranted, inflexible, and punitive practices that create life-threatening barriers to care. In the USA, opioid use disorder care is maximally disruptive. Minimally disruptive medicine (MDM) is a framework that focuses on achieving patient goals while imposing the smallest possible burden on patients' lives. Using MDM framing, we highlight how current medical practices and policies worsen the burden of treatment and illness, compound life demands, and strain resources. We then offer suggestions for programmatic and policy changes that would reduce disruption to the lives of those seeking care, improve health care quality and delivery, begin to address disparities and inequities, and save lives.

Citing Articles

Lessons from the National institutes of health innovation corps program: defining barriers to developing and commercializing novel solutions for persons with opioid use disorder.

Heshmatipour M, Duvernay T, Hite D, Versi E, Hite M, Reeser D Addict Sci Clin Pract. 2025; 20(1):25.

PMID: 40069887 PMC: 11899014. DOI: 10.1186/s13722-025-00554-1.


"Just Be Relentless," Lessons Learned from In-Hospital Addiction Consult Service Implementation.

Williams B, Patten A, Peng L, Englander H J Gen Intern Med. 2025; .

PMID: 39789272 DOI: 10.1007/s11606-024-09263-y.


"I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.

Frank D, Bennett A, Cleland C, Meyerson B, Russell D, Walters S J Subst Use Addict Treat. 2024; 170:209616.

PMID: 39722353 PMC: 11885047. DOI: 10.1016/j.josat.2024.209616.


Patient experiences of buprenorphine dispensing from a mobile medical unit.

Messmer S, Elmes A, Infante A, Patterson A, Smith M, Murphy A Addict Sci Clin Pract. 2024; 19(1):53.

PMID: 39026326 PMC: 11264859. DOI: 10.1186/s13722-024-00484-4.


Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.

Couch J, Whitcomb M, Buchheit B, Dorr D, Malinoski D, Korthuis P Harm Reduct J. 2024; 21(1):125.

PMID: 38937779 PMC: 11210005. DOI: 10.1186/s12954-024-01043-5.


References
1.
ODonnell J, Tanz L, Gladden R, Davis N, Bitting J . Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls - United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021; 70(50):1740-1746. PMC: 8675656. DOI: 10.15585/mmwr.mm7050e3. View

2.
Simon C, Vincent L, Coulter A, Salazar Z, Voyles N, Roberts L . The Methadone Manifesto: Treatment Experiences and Policy Recommendations From Methadone Patient Activists. Am J Public Health. 2022; 112(S2):S117-S122. PMC: 8965191. DOI: 10.2105/AJPH.2021.306665. View

3.
Frank D, Mateu-Gelabert P, Perlman D, Walters S, Curran L, Guarino H . "It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives. Harm Reduct J. 2021; 18(1):88. PMC: 8364307. DOI: 10.1186/s12954-021-00535-y. View

4.
Leppin A, Montori V, Gionfriddo M . Minimally Disruptive Medicine: A Pragmatically Comprehensive Model for Delivering Care to Patients with Multiple Chronic Conditions. Healthcare (Basel). 2016; 3(1):50-63. PMC: 4934523. DOI: 10.3390/healthcare3010050. View

5.
Serrano V, Spencer-Bonilla G, Boehmer K, Montori V . Minimally Disruptive Medicine for Patients with Diabetes. Curr Diab Rep. 2017; 17(11):104. DOI: 10.1007/s11892-017-0935-7. View